Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) generates a steady flow of news as a commercial-stage biopharmaceutical company focused on vaccines for infectious diseases. News coverage commonly highlights developments related to its adult hepatitis B vaccine HEPLISAV-B®, its CpG 1018® adjuvant platform, and a growing pipeline of adjuvanted vaccine candidates.
Investors and observers following DVAX news will see regular updates on financial results, including quarterly earnings releases filed via Form 8-K, where Dynavax reports HEPLISAV-B net product revenue, total revenues, and adjusted EBITDA, along with commentary on market share trends in the U.S. adult hepatitis B vaccine market. These releases often include forward-looking guidance and discussion of capital allocation decisions such as share repurchase authorizations.
Another major category of Dynavax news involves clinical and pipeline milestones. The company issues press releases on topline data from its Phase 1/2 shingles vaccine trial for Z-1018, describing immunogenicity, tolerability and head-to-head comparisons with Shingrix®. Additional updates cover progress in its plague vaccine program funded by the U.S. Department of Defense, its pandemic influenza adjuvant program using CpG 1018 with H5N1 influenza vaccine, and its investigational Lyme disease vaccine candidate.
Corporate and strategic news items include participation in healthcare investor conferences, announcements of conference calls and webcasts, and collaboration agreements. Notably, Dynavax and Vaxart announced an exclusive license and collaboration for an investigational oral COVID-19 vaccine candidate, and Sanofi has announced an agreement to acquire Dynavax through a cash tender offer and subsequent merger, subject to customary conditions.
By tracking the DVAX news feed, readers can monitor how Dynavax’s commercial performance, clinical data, collaborations and corporate transactions evolve over time. This page aggregates company press releases and related disclosures so that users can review financial updates, pipeline progress and strategic announcements in one place.
Dynavax Technologies Corporation (Nasdaq: DVAX) will report its third quarter 2021 financial results on November 4, 2021, after market close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET. Interested parties can access the webcast via the company’s investors' section. Dynavax is known for developing HEPLISAV-B, a hepatitis B vaccine, and is advancing its CpG 1018 adjuvant through research collaborations targeting vaccines for various diseases.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the granting of nonstatutory stock options for 115,000 shares to a new employee, effective October 18, 2021. The options have an exercise price of $17.14, aligned with the stock's closing price on the grant date. These options have a 7-year term and vest over three years, with one-third vesting after one year and the remainder in monthly installments. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and follows their 2021 Inducement Award Plan for new hires.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced positive topline results from Valneva's Phase 3 trial of the inactivated COVID-19 vaccine candidate, VLA2001, which utilizes Dynavax's CpG 1018 adjuvant. The trial met co-primary endpoints, demonstrating superiority over AstraZeneca's AZD1222 in geometric mean titers of neutralization antibodies and non-inferiority in seroconversion rates among adults aged 30 and older. VLA2001 showed a favorable tolerability profile with significantly fewer adverse events compared to AZD1222. Dynavax supports Valneva's continued development of the vaccine.
Dynavax Technologies Corporation (Nasdaq: DVAX) has secured a $22 million agreement with the U.S. Department of Defense to develop a recombinant plague vaccine using its CpG 1018 adjuvant over two and a half years. This collaboration includes a planned Phase 2 clinical trial, expected to commence in 2022, to assess the vaccine's immunogenicity, safety, and tolerability for adults aged 18 to 55 years. The initiative aims to enhance vaccine effectiveness and could lead to future commercial agreements with the U.S. government.
On October 1, 2021, Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of 40,000 nonstatutory stock options to a newly-hired employee as part of their inducement for joining the company. The options are priced at $16.84 per share, equal to the stock's closing price on the grant date. They have a seven-year term, vesting over three years, with one-third vesting after one year and the remainder vesting monthly. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan.
Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in several upcoming investor conferences, showcasing its commitment to vaccine development. Key presentations include the 2021 Cantor Virtual Global Healthcare Conference on September 30 at 12:00 p.m. E.T., the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on October 5 at 12:00 p.m. E.T., and the H.C. Wainwright 2nd Hepatitis B Virus Virtual Conference on October 13 at 12:00 p.m. E.T.. All events will be available via live webcast on their website's 'Events & Presentations' page.
On September 22, 2021, Dynavax Technologies (Nasdaq: DVAX) announced positive results from Clover Biopharmaceuticals' Phase 2/3 SPECTRA trial for their COVID-19 vaccine candidate, SCB-2019, adjuvanted with Dynavax's CpG 1018. The trial, involving over 30,000 participants, demonstrated 100% efficacy against severe COVID-19 and 84% against moderate-to-severe cases, achieving a 79% efficacy against the Delta variant. The vaccine showed a favorable safety profile, with adverse events balanced between vaccine and placebo groups. Clover plans to seek regulatory approvals in Q4 2021, potentially launching the vaccine by year-end.
Dynavax Technologies (Nasdaq: DVAX) announced that Valneva SE received a termination notice from the UK government regarding its COVID-19 vaccine supply agreement for VLA2001. Despite this, Valneva plans to continue clinical trials for VLA2001, with results expected in Q4 2021. Dynavax reiterated a potential revenue opportunity of $300-$400 million for its CpG 1018 adjuvant in 2021, contingent upon ongoing partnerships. There are concerns regarding the impact on Dynavax if Valneva cancels any purchase orders for CpG 1018, but no cancellations have occurred yet.
Dynavax Technologies Corporation (Nasdaq: DVAX) announces that CEO Ryan Spencer will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021.
The on-demand presentation will be accessible starting September 13, 2021, at 7:00 a.m. E.T. via the Company's Investors section. Dynavax focuses on the development and commercialization of vaccines, including its first product, HEPLISAV-B®, for Hepatitis B prevention.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the granting of nonstatutory stock options for 224,000 shares to 8 new employees as an inducement for their employment. The options, priced at $19.00 per share, match the closing stock price on the grant date, September 1, 2021. The options vest over three years, with one-third vesting on the first anniversary and the remainder vesting in monthly increments. This grant complies with Nasdaq Listing Rule 5635(c)(4) and follows the company's 2021 Inducement Award Plan.
FAQ
What is the current stock price of Dynavax Technolo (DVAX)?
What is the market cap of Dynavax Technolo (DVAX)?
